COVID-19 in teriflunomide-treated patients with multiple sclerosis: A case report and literature review
- 1 February 2021
- journal article
- review article
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 48, 102734
Abstract
No abstract availableKeywords
Funding Information
- Biogen
- Merck
- Roche
This publication has 20 references indexed in Scilit:
- The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemicMultiple Sclerosis and Related Disorders, 2020
- Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemicNeurology, 2020
- An Italian programme for COVID-19 infection in multiple sclerosisThe Lancet Neurology, 2020
- Inhibiting pyrimidine biosynthesis impairs Ebola virus replication through depletion of nucleoside pools and activation of innate immune responsesAntiviral Research, 2018
- Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteriaThe Lancet Neurology, 2018
- Broad-spectrum inhibition of common respiratory RNA viruses by a pyrimidine synthesis inhibitor with involvement of the host antiviral responseJournal of General Virology, 2017
- Infection-related health care utilization among people with and without multiple sclerosisMultiple Sclerosis Journal, 2016
- Dramatically changing rates and reasons for hospitalization in multiple sclerosisNeurology, 2014
- Teriflunomide and Its Mechanism of Action in Multiple SclerosisDrugs, 2014
- Inhibition of Pyrimidine Biosynthesis Pathway Suppresses Viral Growth through Innate ImmunityPLOS Pathogens, 2013